244 related articles for article (PubMed ID: 1711411)
1. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
[TBL] [Abstract][Full Text] [Related]
2. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
3. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
4. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
5. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
6. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.
Heikkilä R; Aho K; Heliövaara M; Hakama M; Marniemi J; Reunanen A; Knekt P
Cancer; 1999 Jul; 86(2):312-5. PubMed ID: 10421267
[TBL] [Abstract][Full Text] [Related]
7. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
8. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones.
Baradaran N; Ahmadi H; Salem S; Lotfi M; Jahani Y; Baradaran N; Mehrsai AR; Pourmand G
Prostate; 2009 Dec; 69(16):1744-50. PubMed ID: 19676082
[TBL] [Abstract][Full Text] [Related]
9. Serum androgens: associations with prostate cancer risk and hair patterning.
Demark-Wahnefried W; Lesko SM; Conaway MR; Robertson CN; Clark RV; Lobaugh B; Mathias BJ; Strigo TS; Paulson DF
J Androl; 1997; 18(5):495-500. PubMed ID: 9349747
[TBL] [Abstract][Full Text] [Related]
10. Hormonal consequences of orchidectomy for carcinoma of the prostate. With special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels.
Boccon-Gibod L; Laudat MH; Guiban D; Steg A
Eur Urol; 1988; 15(1-2):99-102. PubMed ID: 3215246
[TBL] [Abstract][Full Text] [Related]
11. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
12. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
Chen C; Weiss NS; Stanczyk FZ; Lewis SK; DiTommaso D; Etzioni R; Barnett MJ; Goodman GE
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1410-6. PubMed ID: 14693730
[TBL] [Abstract][Full Text] [Related]
13. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
Mo ZN; Huang X; Zhang SC; Yang JR
J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
15. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
Hsing AW; Comstock GW
Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
[TBL] [Abstract][Full Text] [Related]
16. Serum sex hormone binding globulin and testosterone binding after estradiol administration, castration, and their combination in men with prostatic carcinoma.
Leinonen P; Hammond GL; Lukkarinen O; Vihko R
Invest Urol; 1979 Jul; 17(1):24-7. PubMed ID: 571863
[TBL] [Abstract][Full Text] [Related]
17. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III).
Rohrmann S; Nelson WG; Rifai N; Kanarek N; Basaria S; Tsilidis KK; Smit E; Giovannucci E; Platz EA
Urology; 2007 Apr; 69(4):708-13. PubMed ID: 17445656
[TBL] [Abstract][Full Text] [Related]
18. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
19. Sex steroids and bone turnover markers in men with symptomatic vertebral fractures.
Tuck SP; Scane AC; Fraser WD; Diver MJ; Eastell R; Francis RM
Bone; 2008 Dec; 43(6):999-1005. PubMed ID: 18817902
[TBL] [Abstract][Full Text] [Related]
20. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
